Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
As of early March 2026, the long-standing dominance of the S&P 500 (NYSEARCA: VOO) has met its most significant challenge in nearly a decade. For the first time since the mid-2010s, international equity markets are not just keeping pace with their American counterparts but are decisively outperforming them. While
JACKSONVILLE BEACH, Fla., March 5, 2026 (SEND2PRESS NEWSWIRE) -- Industrial SalesLeads released its February 2026 Planned Capital Project Spending Report for the Industrial Manufacturing sector. The firm tracks industrial capital investment activity across North America, including facility expansions, new plant construction, and significant equipment modernization projects.
Eli Lilly (NYSE: LLY) launches Employer Connect platform on March 5, 2026, offering Zepbound tirzepatide KwikPen at $449 across all doses to expand employer-sponsored obesity coverage.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Bristol-Myers Squibb (NYSE:BMY) and its peers.
As of March 4, 2026, the global financial landscape is witnessing a seismic shift in corporate strategy. After years of cautious maneuvering and high interest rates, the "animal spirits" of the boardroom have returned with a vengeance. Leading investment banks, including Morgan Stanley (NYSE: MS), are now projecting a staggering
NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a precarious regulatory and legal bind. As of March 4, 2026, the company finds itself at a crossroads, battling
As the first quarter of 2026 unfolds, the equity markets are at a historic crossroads. Morgan Stanley (NYSE:MS) has stunned Wall Street with a revised year-end target for the S&P 500, projecting the index will reach 7,800—a bold 14% gain from current levels. This bullish stance
The final trading week of February 2026 has laid bare a striking fracture in the U.S. equity markets. While the technology sector continues to feast on a relentless AI-driven "execution" cycle, the broader market indices are increasingly weighed down by deep-seated structural issues in the healthcare and industrial sectors.
In a dramatic departure from his historically cautious stance, Mike Wilson, Chief U.S. Equity Strategist at Morgan Stanley (NYSE: MS), has stunned Wall Street by raising the firm’s 12-month S&P 500 price target to a lofty 7,800. This projection, released as the market moves through the
As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional "Big Pharma" mainstay, Lilly has transcended its industry peers to become a high-octane growth engine, recently flirting
In a defining moment for global financial markets, the S&P 500 Index officially breached the 7,000-point mark for the first time in history on January 28, 2026. This monumental achievement underscores a multi-year bull run that has defied skeptics, survived geopolitical volatility, and transitioned from a narrow, tech-led
As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the undisputed "darling" of the global equity markets, propelled by the unprecedented success of its GLP-1 (glucagon-like peptide-1) agonists, Ozempic and Wegovy. However, the early months [...]
Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.
